SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

Summit shares drop after US FDA declines to approve lung cancer drug

Summit shares drop after US FDA declines to approve lung cancer drug Nov 16 (Reuters) - Shares of Su

SMMT

Story updates

11:44:29 AM UTC
SquawkNews
By Connor HartShares of Summit Therapeutics fell after the Food and Drug Administration didn't approve the company's investigational treatment for certain types of lung cancer.The stock dropped 18%, to $11.59, in premarket trading Monday. Through Friday's close, shares have lost about a fifth of th…

Related stories